



STATE OF MICHIGAN

GRETCHEN WHITMER
GOVERNOR

DEPARTMENT OF HEALTH AND HUMAN SERVICES
LANSING

AMY EPKEY
ACTING DIRECTOR

Standing Recommendation on Respiratory Virus Vaccines 2026-2027

In my role as chief medical executive for the State of Michigan, I, Natasha Bagdasarian, MD, MPH, FIDSA, FACP, issue the following standing recommendation under MCL 333.26369:

As of October 15, 2026, health care providers in Michigan should refer to the respiratory virus immunization recommendations produced by the American Medical Association, when determining which vaccines their patients should receive and the timing for their administration for the 2026-2027 respiratory season.

In consultation with the Michigan Department of Health and Human Services Division of Immunizations, I have reviewed current vaccine schedule recommendations produced by the American Medical Association ([AMA Respiratory Recommendations](#)), and aligned with evidence and guidance from the American Academy of Family Physicians, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, Vaccine Integrity Project, and Infectious Diseases Society of America, and find them to be well-evidenced and based on rigorous review. Vaccines are the best defense against severe outcomes from COVID-19, RSV, and influenza infections. Employing these schedules will contribute to the advancement of the health of Michigan's residents and prevent severe, potentially fatal, negative outcomes during this respiratory season. I encourage health care providers, health care systems, and health care payers to remove barriers to vaccine access where possible.

Further, the standing recommendation issued on September 19, 2025, remains in effect. That recommendation states, in pertinent part:

Any person over the age of six months without contraindication who has not received a dose of a Food and Drug Administration- (FDA) approved or authorized 2025-2026 COVID-19 vaccine may be considered to have an underlying condition that puts them at high risk for severe outcomes from COVID-19 and is thus eligible to receive an age-appropriate dose.

This guidance is applicable to persons seeking the 2026-2027 COVID-19 vaccine.¹
This recommendation should not supersede clinical judgement in decision making with individual patients.

This standing recommendation is in effect until rescinded.

SIGNATURE:



Natasha Bagdasarian, MD, MPH, FIDSA, FACP
Chief Medical Executive



October 15, 2026
Date Signed/Effective

¹ See, e.g., [COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season | Coronavirus \(COVID-19\) | JAMA | JAMA Network](#)